-

$undefined

N/A

(N/A)

Arvinas Inc. NASDAQ:ARVN Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and "undruggable" targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.

Location: | Website: arvinas.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

542.1M

Cash

1.122B

Avg Qtr Burn

-64.58M

Short % of Float

14.93%

Insider Ownership

7.22%

Institutional Own.

Qtr Updated

09/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Vepdegestrant (ARV-471) (oral ER-targeting PROTAC® protein degrader) + palbociclib Details Breast cancer, Cancer, Solid tumor/s	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vepdegestrant (ARV-471)(oral ER-targeting PROTAC® protein degrader) Details Breast cancer, Cancer, Solid tumor/s Big Mover™ Suspected Mover™ Susp. Mover™	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vepdegestrant (ARV-471) Details Cancer, Breast cancer, Solid tumor/s	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vepdegestrant (ARV-471)+CDK7 inhibitor (samuraciclib) Details Cancer, Solid tumor/s	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARV-766 +/- abiraterone Details Solid tumor/s, Castration-resistant prostate cancer, Prostate cancer, Cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bavdegalutamide (ARV-110) (PROTAC protein degrader) +/- abiraterone Details Prostate cancer, Cancer, Castration-resistant prostate cancer, Solid tumor/s	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vepdegestrant (ARV-471)+CDK4 inhibitor Details Solid tumor/s, Cancer, Breast cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Vepdegestrant (ARV-471) Details Cancer, Breast cancer, Solid tumor/s	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARV-393 [PROTAC BCL6 degrader] Details Cancer, B-cell lymphoma, Blood cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ARV-102 (PROTAC® LRRK2 degrader) Details Neurodegenerative disease	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.